Clifford Chance has advised the U.S. Department of Commerce. The U.S. Department of Commerce has finalized a US$1 billion award under the CHIPS and Science Act...
U.S. Department of Commerce Awards $1 Billion CHIPS Act Grant to Anderon for Quantum Semiconductor Foundry
Mitsui Increases Stake in Nutrinova and Implements Strategic Upstream Integration
Clifford Chance has advised Mitsui & Co., Ltd. and Nutrinova Netherlands B.V. Linklaters, LLP has advised Celanese Corporation as legal counsel; A&O Shearman has advised Celanese...
U.S. Department of Commerce Awards US$250 Million for Silicon Carbide Semiconductor R&D to I-Pulse
Clifford Chance has advised the U.S. Department of Commerce CHIPS Program Office. The U.S. Department of Commerce CHIPS Program Office has announced a US$250 million research...
USA Rare Earth Secures Up to $1.6 Billion in Federal Incentives from Department of Commerce
Clifford Chance has advised the U.S. Department of Commerce CHIPS Program Office. The U.S. Department of Commerce CHIPS Program Office has finalized an agreement to provide...
Creation of First Pan-Baltic Tower Company Through Tele2 and GCI Joint Venture
Clifford Chance and TEGOS have advised Tele2 AB. Freshfields has advised Global Communications Infrastructure, LLC (GCI), backed by Manulife Investment Management. Tele2 AB, a leading Swedish...
Keymed Biosciences’ Licensing Agreement With Ouro Medicines LLC
Clifford Chance advised Keymed Biosciences on the deal. Keymed Biosciences (HKSe: 02162) signed a licensing agreement granting Platina the exclusive worldwide rights to develop, manufacture and...
Keymed Biosiences’ Out-Licensing Transaction With Timberlyne Therapeutics Inc.
Clifford Chance advised Keymed Biosciences on the deal. Timberlyne Therapeutics, Inc. announced its US$180 million Series A financing to advance the development of CM313. Investors Abingworth,...
Sanofi’s Acquisition Of Aficamten Rights From Corxel Pharmaceuticals
Clifford Chance advised Sanofi on the deal. Global healthcare company Sanofi announced the acquisition of exclusive rights to develop and commercialise aficamten in Greater China from...
Sanofi’s Acquisition Of Aficamten Rights From Corxel Pharmaceuticals
Clifford Chance advised Sanofi on the deal. Global healthcare company Sanofi announced the acquisition of exclusive rights to develop and commercialise aficamten in Greater China from...
Keymed Biosciences Inc.’s Out-Licensing Transaction With Belenos Biosciences
Clifford Chance has advised Keymed Biosciences (Chengdu) Co., Ltd. on the deal. Keymed Biosciences (Chengdu) Co., Ltd. completed an out-licensing transaction with Belenos Biosciences, Inc.to exclusively...
Greenway Grameen’s $6.5 Million Financing For Carbon Offset Project in India
Clifford Chance advised Asian Development Bank (ADB) on the deal. The Asian Development Bank (ADB) and Greenway Grameen Infra Private Limited signed a $6.5 million senior...
Pegasus’ Business Combination with SCHMID and Listing of Combined Entity on NYSE
Clifford Chance advised Pegasus Digital Mobility Acquisition Corp. while Gleiss Lutz represented Gebr. Schmid GmbH. Gebr. Schmid GmbH (SCHMID Group) announced its planned listing on the New...